Company intelligence / Profile preview

Aker BioMarine

Ownership: Public · AKBM
Employees: ~373
Development stage: Commercial

Overview

Multiple studies showing benefits of krill oil for omega-3 deficiency in lupus patients, osteoarthritis of the knee, and skin health. Recent research indicates krill oil can slow down aging and improve quality of life.

Therapeutic areas: Metabolic DisordersImmunologyRheumatologyCardiovascularNeurology
Modalities: Krill-derived nutritional products
Industry: Food & Nutrition

Drug pipeline

2 assets

Superba Krill

Commercial

Indications: Heart health, Brain health, Joint health

1 more asset in the full pipeline.

Request access →

Partnerships

US military (research study)Pure Science Triathlon teamNorsemanNorwegian Board AssociationBarentz International B.V.Norwegian Institute of Marine Research

Beyond the preview

Go deeper on Aker BioMarine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aker BioMarine.

Explore the full profile